Squarepoint’s Edwards Lifesciences EW Stock Holding History

Squarepoint’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,600	Closed	-$208K	–	4587
2026 Q1	$208K	Buy	+2,600	New	+$214K	﹤0.01%	3941
2025 Q2	–	Sell	-5,300	Closed	-$384K	–	4643
2025 Q1	$384K	Sell	5,300 -31,100	-85%	-$2.23M	﹤0.01%	3535
2024 Q4	$2.69M	Sell	36,400 -180,200	-83%	-$12.6M	﹤0.01%	2155
2024 Q3	$14.3M	Buy	216,600 +203,000	+1,493%	+$14.7M	0.02%	759
2024 Q2	$1.26M	Sell	13,600 -5,500	-29%	-$487K	﹤0.01%	2395
2024 Q1	$1.83M	Buy	19,100 +11,800	+162%	+$991K	﹤0.01%	2139
2023 Q4	$557K	Sell	7,300 -21,800	-75%	-$1.52M	﹤0.01%	2928
2023 Q3	$2.02M	Sell	29,100 -9,300	-24%	-$747K	0.01%	1819
2023 Q2	$3.62M	Buy	+38,400	New	+$3.34M	0.01%	1268
2022 Q1	–	Sell	-21,900	Closed	-$2.84M	–	3030
2021 Q4	$2.84M	Sell	21,900 -1,600	-7%	-$187K	0.01%	1060
2021 Q3	$2.66M	Buy	23,500 +1,600	+7%	+$183K	0.01%	1067
2021 Q2	$2.27M	Hold	21,900	–	–	0.01%	1118
2021 Q1	$1.83M	Buy	+21,900	New	+$1.85M	0.01%	1122

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Squarepoint's EW Position: Q2 2026 in Review

Squarepoint increased its Edwards Lifesciences (EW) stake by 77% in Q2 2026, buying an estimated $991K and bringing the position to 27,261 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2183.

Squarepoint first reported a position in EW in Q4 2014 and has held it in 37 quarters since. The position peaked at $65.2M in Q4 2022. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Squarepoint held 27,261 shares of Edwards Lifesciences worth $2.47M as of Q2 2026.
Squarepoint bought 11,835 Edwards Lifesciences shares in Q2 2026, an estimated $991K.
Edwards Lifesciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2183 holding.
Squarepoint first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 37 quarters since.
Squarepoint's Edwards Lifesciences position peaked at $65.2M in Q4 2022.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.